Session – EAU17 London

New light on prostate cancer

Industry session by STEBA BIOTECH

Sunday 26 March
17:45 - 19:15

Location:

Room 7, Capital suite (level 3)

17:45 - 17:50

Welcome and introduction

17:50 - 18:05

Should we treat Gleason 6 prostate cancer?

M. Wirth, Dresden (DE)

18:05 - 18:20

Data on phase III pivotal trials of TOOKAD® Soluble vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer

M. Emberton, London (GB)

18:20 - 18:35

How will focal therapy change current treatment of localized prostate cancer

N. Mottet, Saint-Étienne (FR)

18:35 - 18:50

Technical aspect of VTP Surgery

A.R. Azzouzi, Angers (FR)

18:50 - 19:05

Introduction into the mechanism of action of vascular-targeted photodynamic therapy - TOOKAD® Soluble

A. Scherz, Rehovot (IL)

19:05 - 19:15

Question and answers